Founded in 1996 as a spinoff from the Harvard-MIT Division of Health Sciences and Technology, NeuroMetrix is a commercial stage, bioelectrical and digital medicine company driving innovation to address chronic health conditions including chronic pain and diabetes. Building on its roots in diagnostics technology, NeuroMetrix applied the same science to develop its lead product, QuellÂŽ, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheckÂŽ, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. Based in Waltham, Mass., NeuroMetrix maintains an active research effort and has several pipeline programs. Source
No articles found.
Spectrum Pharmaceuticals is a leading biotechnology company with a focus in Oncolo...
Spectrum Pharmaceuticals is a leading biotechno...
Scopus BioPharma develops small molecule therapeutics leveraging world-class exper...
Scopus BioPharma develops small molecule therap...
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedica...
Global Blood Therapeutics, Inc. (GBT) is a clin...
At Affimed, we are committed to improving outcomes for patients with cancer. Our s...
At Affimed, we are committed to improving outco...
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, de...
STAAR, which has been dedicated solely to ophth...
Celldex is developing targeted therapeutics to address devastating diseases for wh...
Celldex is developing targeted therapeutics to ...
At Delee were fundamentally changing not only the way cancer is detected but also...
At Delee were fundamentally changing not only ...
Join the National Investor Network and get the latest information with your interests in mind.